ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,303.27
0.12%
Dow Jones
40,003.59
0.34%
US Dollar vs MXN
16.6086
0.00%
Brent Oil
83.76
0.00%
Bitcoin
67,103.65
0.24%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Protara Therapeutics Inc (TARA)

  7. Protara Therapeutics Inc (TARA) Noticias

TARA

Protara Therapeutics (TARA)

Protara Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:TARA
FechaHoraFuenteTítuloSímboloCompañía
17/05/202418:48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARAProtara Therapeutics Inc
09/05/202423:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:TARAProtara Therapeutics Inc
09/05/202415:31Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:TARAProtara Therapeutics Inc
02/05/202407:00GlobeNewswire Inc.Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:TARAProtara Therapeutics Inc
05/04/202407:04GlobeNewswire Inc.Protara Therapeutics Announces Oversubscribed $45 Million Private Placement FinancingNASDAQ:TARAProtara Therapeutics Inc
05/04/202407:02GlobeNewswire Inc.Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral NutritionNASDAQ:TARAProtara Therapeutics Inc
05/04/202407:00GlobeNewswire Inc.Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBCNASDAQ:TARAProtara Therapeutics Inc
13/03/202407:00GlobeNewswire Inc.Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:TARAProtara Therapeutics Inc
28/02/202407:00GlobeNewswire Inc.Protara Therapeutics to Present at the TD Cowen 44th Annual Health Care ConferenceNASDAQ:TARAProtara Therapeutics Inc
30/11/202307:30GlobeNewswire Inc.Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic OncologyNASDAQ:TARAProtara Therapeutics Inc
03/11/202307:31Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:TARAProtara Therapeutics Inc
03/11/202307:20Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TARAProtara Therapeutics Inc
03/11/202307:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TARAProtara Therapeutics Inc
03/11/202307:00GlobeNewswire Inc.Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business UpdateNASDAQ:TARAProtara Therapeutics Inc
23/10/202307:00GlobeNewswire Inc.Protara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic MalformationsNASDAQ:TARAProtara Therapeutics Inc
20/09/202307:30GlobeNewswire Inc.Protara Therapeutics Announces Dosing of First Patient in Phase 1b/2 ADVANCED-2 Trial of TARA-002 in NMIBC Patients with High Grade Carcinoma in SituNASDAQ:TARAProtara Therapeutics Inc
05/09/202306:30GlobeNewswire Inc.Protara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:TARAProtara Therapeutics Inc
03/08/202307:00GlobeNewswire Inc.Protara Therapeutics Announces Second Quarter 2023 Financial Results and Business UpdateNASDAQ:TARAProtara Therapeutics Inc
27/06/202318:26Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:TARAProtara Therapeutics Inc
08/06/202315:07Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:TARAProtara Therapeutics Inc
15/05/202307:00GlobeNewswire Inc.Protara Therapeutics Announces Dosing of First Patients in Phase 1b ADVANCED-1EXP Trial of TARA-002 in NMIBC Patients with Carcinoma in SituNASDAQ:TARAProtara Therapeutics Inc
04/05/202307:11Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:TARAProtara Therapeutics Inc
04/05/202307:00GlobeNewswire Inc.Protara Therapeutics Announces First Quarter 2023 Financial Results and Business UpdateNASDAQ:TARAProtara Therapeutics Inc
02/05/202307:00GlobeNewswire Inc.Protara Therapeutics Receives Regulatory Clearance from FDA to Commence Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic MalformationsNASDAQ:TARAProtara Therapeutics Inc
28/04/202307:00GlobeNewswire Inc.Protara Therapeutics Announces Positive Preliminary Data from ADVANCED-1 Phase 1a Dose Escalation Trial of TARA-002 in NMIBC Supporting Advancement into Phase 2 Clinical DevelopmentNASDAQ:TARAProtara Therapeutics Inc
26/04/202315:12Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:TARAProtara Therapeutics Inc
26/04/202315:10Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:TARAProtara Therapeutics Inc
26/04/202315:06Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:TARAProtara Therapeutics Inc
08/03/202315:11Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:TARAProtara Therapeutics Inc
08/03/202307:21Edgar (US Regulatory)Annual Report (10-k)NASDAQ:TARAProtara Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:TARA

Su Consulta Reciente

COIN
LYNUSD
USOTC
HRIBF
Horiba (PK)
NYSE
HTGZ.CL
LSE
GDX3
3x Gold Mine
BIT
EUBO
Wisdomtree European Unio...
LATK
MOFIUSDT
MobiFi
NASDAQ
AXSKX
AXS Sustainable Income F...
LQID
CMCTETH
BIT
P1KE46
BNP Paribas Issuance
BIT
NMIDB
Augustum Italian Diversi...
LSE
ZY0N
Nat.grid.n.a 27
LBNK
DTHUSDT
DeathWolf
EU
H873T
H873T
ASX
EGP
LSE
RJ01
Natwest.m 27
EU
E655T
E655T
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados